Evidence map›Paper›PMID 40632690›Full record

ArticleHuman psychopharmacology2025

Psychometric Properties of the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult-Aged-Spectrum (SCOPA).

Levi J M Schuurman, Sjacko Sobczak, Julie E M Schulkens, Benno P F Balter, Sebastiaan P J van Alphen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Levi J M SchuurmanDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience (FPN), Maastricht University, Maastricht, the Netherlands.ORCID 0009-0008-5296-414X
Sjacko SobczakDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience (FPN), Maastricht University, Maastricht, the Netherlands.
Julie E M SchulkensClinical Center of Excellence for Older Adults with Personality Disorders, Mondriaan, Mental Health Center, Heerlen, Maastricht, the Netherlands.ORCID 0000-0002-0279-4137
Benno P F BalterDepartment of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience (FPN), Maastricht University, Maastricht, the Netherlands.
Sebastiaan P J van AlphenClinical Center of Excellence for Older Adults with Personality Disorders, Mondriaan, Mental Health Center, Heerlen, Maastricht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePatient-reported side-effect questionnaires contribute to balanced decisions regarding treatment strategy among patients with mental health disorders. However, current side-effect questionnaires are less suitable for older adults because they often lack age-specific side effects. Therefore, the Scale for Subjective Somatic and Cognitive Complaints of Psychotropic Medication Adult-Aged-Spectrum (SCOPA) was developed to quantify psychotropic side effects across the full adult age spectrum. The aim of this study was to develop and evaluate the reliability and validity of the SCOPA. PROCEDURES: Psychometric properties of the SCOPA were assessed in a Dutch patient population (n = 205, age 18-86 years) and a general population (n = 281, age 18-87 years). Reliability of the subscales was measured through average inter-item correlation and Cronbach's alphas. Construct validity was analysed by exploratory factor analysis.

resultsAverage inter-item correlation and Cronbach's alphas of the subscales of the SCOPA were moderate to good. Exploratory factor analyses supported a two-factor solution, labelled as complaints in somatic and cognitive domains.

conclusionsThis study showed that the SCOPA has promising psychometric qualities and practical capability to evaluate the side-effect burden of treatment with psychotropic medication across the adult-aged-spectrum. However, more research is needed to cross-validate these results in the field's pursuit of increased patient safety.

Indexed as

CognitionPsychometricsPsychotropic DrugsAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMental DisordersMiddle AgedNetherlandsReproducibility of ResultsSurveys and QuestionnairesYoung AdultPsychotropic Drugsconstruct validityinternal consistencyolder adultspharmacotherapypsychotropic medicationside effects

Identifiers

PMID40632690
PMCPMC12240232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.